Results 211 to 220 of about 4,984,276 (289)

Megakaryocyte dysplasia in primary myelofibrosis [PDF]

American Journal of Hematology, 2010
openaire   +2 more sources

Valore predittivo di variabili clinico-laboratoristiche in pazienti con mielofibrosi trattati con inibitore di JAK-1/2 [PDF]

, 2011
CARAMAZZA, Domenica
core  

Glutathione reductase and nitroblue tetrazolium reduction deficiencies in neutrophils of patients with primary idiopathic myelofibrosis.

, 1984
Axel Périanin, M T Labro-Bryskier, Claude Marquetty, J Hakim   +3 more
openalex   +1 more source

Primary myelofibrosis in rheumatic diseases

Научно-практическая ревматология, 2013
Vladimir Ivanovich Vasilyev, V R Gorodetsky, S Kh Sedyshev, O A Logvinenko, N A Probatova, A I Pavlovskaya, M S Eliseyev, A V Smirnov, G R Fadienko   +8 more
doaj   +1 more source

Multiple Aneurysms and Thrombotic Events as Initial Manifestations of Primary Myelofibrosis: A Case Report. [PDF]

Cureus
Manganas K, Bemplidakis T, Papachristou K, Angelara M, Karamanakos G.   +4 more
europepmc   +1 more source

DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies. [PDF]

Clin Epigenetics
Dursun Torlak E, Tharmapalan V, Kricheldorf K, Schifflers J, Caduc M, Zenke M, Koschmieder S, Wagner W.   +7 more
europepmc   +1 more source

Warm Autoimmune Hemolytic Anemia as a Rare Presentation of Pre-fibrotic Primary Myelofibrosis. [PDF]

Cureus
Lai SY, Lo AE, Wu P.
europepmc   +1 more source

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]

, 2018
Abboud, Camille N.
core   +1 more source

Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry. [PDF]

Hemasphere
Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Morrone L, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Boldrini V, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larràn A, Andreasson B, Vannucchi AM, Barbui T.   +17 more
europepmc   +1 more source

Treatment of <i>JAK2</i> V617F-positive primary myelofibrosis and advanced chronic myelogenous leukemia with ruxolitinib and flumatinib: a case report. [PDF]

Ann Med Surg (Lond)
Zhu F, Wang H, Qiu L.
europepmc   +1 more source